Efficacy of Omalizumab against Japanese Cedar pollinosis in clinical practice
Momoko Takeda, Hiroshi Utsunomiya, Toshio Miki · 2025
Read Efficacy of Omalizumab against Japanese Cedar pollinosis in clinical practice by Momoko Takeda, Hiroshi Utsunomiya, Toshio Miki (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12664126.txt.
Description
Momoko Takeda, Hiroshi Utsunomiya, and Toshio Miki wrote this 2025 study of a drug for Japanese cedar pollinosis in real clinic use. The allergy hits over 40 percent of Japan's population and is a major public health issue. The drug, omalizumab, works well but costs a lot, so doctors must choose patients with care.
The team looked back at 42 patients treated with the drug from 2021 to 2024. Patients rated their own response on a three-step scale. In a later subset of 23 patients, full symptom scores allowed sharper measures of the effect. The group held 30 men, and ages ran from 12 to 80 years. Symptoms improved in 38 patients, or 90 percent, with marked improvement in 23. The study weighs who gains most from the drug in daily practice.
Catalog record
| CREATOR | Momoko Takeda, Hiroshi Utsunomiya, Toshio Miki |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 39 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |